Gemcitabine-induced pulmonary toxicity - Case report and review of the literature
Gemcitabine-induced pulmonary toxicity - Case report and review of the literature
复制标题
DOI：
10.1097/00000421-200202000-00021
复制
发表时间：
2002-02-01
影响因子：
2.6
通讯作者：
Mehrotra, B
中科院分区：
文献类型：
--
作者：
Gupta, N;Ahmed, I;Mehrotra, B
吉西他滨是一种嘧啶类似物，具有与阿糖胞苷相似的化学结构和作用机制。已证明吉西他滨是治疗非小细胞肺癌、胰腺癌、尿路上皮癌、乳腺癌和卵巢癌的高活性药物，吉西他滨的耐受性相对良好，骨髓抑制是剂量限制性毒性。吉西他滨的肺毒性相对少见，但却是一种公认的实体，与显著的发病率和死亡率相关。高度怀疑，早期诊断和及时干预与氧气补充，类固醇和利尿剂是必要的，以管理这种并发症的患者。
Gemcitabine is a pyrimidine analog with a similar chemical structure and mechanism of action, as cytarabine. It has been shown to be a highly active agent for non-small cell lung cancer, pancreatic cancer, urothelial cancer, breast cancer and ovarian cancer, Gemcitabine is relatively well tolerated and myelosuppression is the dose-limiting toxicity. Pulmonary toxicity with gemcitabine is relatively uncommon, but a well recognized entity, associated with significant morbidity and mortality. A high index of suspicion, early diagnosis and timely intervention with oxygen supplementation, steroids, and diuretics is necessary to manage patients with this complication.